Vanguard/Roche Claim To Have Serotonin Obesity Target Without Redux AEs
Executive Summary
Vanguard Medica has found a serotonin receptor target that has a role in controlling obesity but is not associated with the cardiovascular side effects of Redux, Vanguard CEO Robert Mansfield told the Chase H&Q Investing in Biotechnology Conference May 10 in London.